Regulatory Deadline Board/2026-23005
Food and Drug Administration · Proposed Rule
Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
58 days left
- Agency
- Food and Drug Administration
- Document type
- Proposed Rule
- Published
- Nov 12, 2026
- Comments close
- Jan 11, 2027
- Status
- 58 days left
- Federal Register number
- 2026-23005
- Docket
- Docket No. FDA-2026-N-12508
More from Food and Drug Administration
Notice · 58 days left
Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information
Notice · 44 days left
Electronic Submission Template for Investigational Device Exemption (IDE) Applications; Draft Guidance for Sponsors and Food and Drug Administration Staff; Availability
Rule · 23 days left
Nonclinical Testing Terminology
Proposed Rule · 23 days left
Nonclinical Testing Terminology
Notice · 16 days left
Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards
Notice · 13 days left
Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability